Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
Anecdotal experience has previously suggested that off-label use of some commonplace drugs may improve survival for patients with ovarian cancer. This meta-analysis of 4 prospective randomised trials looks at the effect of some of these.
Data was obtained from the trials which recorded use of the additional drug treatment. The prime purpose of the trials having been assessment of efficacy of the enzyme inhibitor, Pazopanib. From the data, patients could be subdivided into two groups; those who had received additional drug therapy and those who had not.Finding from the results show that use of off-label drugs was associated with greater co-morbidity. Neither metformin or statin therapy had any effect on survival. Use of betablockers had a negative effect, those patients had worse survival outcomes.
No comments:
Post a Comment